Instrument Inactif

Communiqués Oramed Pharmaceuticals, Inc. Xetra

Actions

Cours en clôture Xetra Autres places de cotation
- ^EUR	-

15/05	Compugen nomme David Silberman directeur financier	MT
13/05	Oramed Pharmaceuticals Inc. annonce la démission de David Silberman en tant que trésorier et secrétaire, à compter du 12 juillet 2024	CI

Oramed Pharmaceuticals : Management Change/Compensation - Form 8-K	13/05	PU
Oramed: Q1 Earnings Snapshot	10/05	AQ
Oramed Pharmaceuticals : Update on the receipt of payments for the Scilex transaction	06/05	PU
Oramed Pharmaceuticals : 13D-Nadav Kidron	26/03	PU
Oramed Pharmaceuticals : Update on the receipt of payments for the Scilex transaction	19/03	PU
Oramed Pharmaceuticals : Other Report or Announcement	18/03	PU
Oramed Pharmaceuticals : Other Report or Announcement	18/03	PU
Oramed Pharmaceuticals : Other Report or Announcement	02/01	PU
Oramed Pharmaceuticals : Other Report or Announcement	24/12	PU
Oramed Pharmaceuticals : Form 8-K - Director Appointment- Dr. Daniel Aghion, effective as of January 1, 2024.	19/12	PU
Oramed: Q3 Earnings Snapshot	10/11	AQ
Oramed Pharmaceuticals : Other Report or Announcement	07/08/23	PU
Oramed Pharmaceuticals : Stalking Horse Stock Purchase Term Sheet - Form 8-K	07/08/23	PU
Oramed Signs Term Sheet with HTIT to Create a Joint Venture to Advance Oral Drug Delivery Technology Globally	02/08/23	PR
Oramed to Present at the 83rd American Diabetes Association Conference	21/06/23	AQ
Oramed to Present at Novel Therapies for Type 2 Diabetes & Obesity Summit	18/05/23	PR
Oramed: Q1 Earnings Snapshot	12/05/23	AQ
ORAMED PHARMACEUTICALS INC. : Change in Directors or Principal Officers (form 8-K)	01/05/23	AQ
Oramed Appoints Ben Shapiro to its Board of Directors	01/05/23	PR
ORAMED PHARMACEUTICALS INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS. (form 10-K)	06/03/23	AQ

Aucun résultat pour cette recherche